Immatics N.V. Updates on IMA203 Cell Therapy for Melanoma
Ticker: IMTX · Form: 6-K · Filed: Oct 10, 2024 · CIK: 1809196
Sentiment: neutral
Topics: clinical-trial-update, oncology, cell-therapy
TL;DR
Immatics drops new melanoma cell therapy data, Phase 3 trial SUPRAME on deck.
AI Summary
On October 10, 2024, Immatics N.V. announced updated Phase 1b clinical data for its ACTengine® IMA203 TCR-T therapy targeting PRAME in melanoma patients. The company also provided an update on the upcoming Phase 3 trial, SUPRAME, which will evaluate IMA203 in metastatic melanoma patients. IMA203 is Immatics' most advanced TCR-based autologous cell therapy.
Why It Matters
This update provides crucial clinical data on Immatics' lead cell therapy candidate, IMA203, potentially impacting its development path and future commercialization for melanoma treatment.
Risk Assessment
Risk Level: medium — Clinical trial updates for novel therapies carry inherent risks related to efficacy, safety, and regulatory approval.
Key Players & Entities
- Immatics N.V. (company) — Registrant and developer of IMA203
- IMA203 (drug) — TCR-T therapy targeting PRAME
- PRAME (target) — Antigen targeted by IMA203
- melanoma (disease) — Indication for IMA203 therapy
- SUPRAME (trial) — Upcoming Phase 3 trial for IMA203
FAQ
What specific updated Phase 1b clinical data was provided for IMA203?
The filing states that updated Phase 1b clinical data on ACTengine® IMA203 TCR-T targeting PRAME in melanoma patients was provided, but the specific data points are not detailed in this excerpt.
What is the name of the upcoming Phase 3 trial for IMA203?
The upcoming Phase 3 trial to evaluate IMA203 in metastatic melanoma patients is named SUPRAME.
What type of therapy is IMA203?
IMA203 is described as Immatics' most advanced TCR-based autologous cell therapy.
What is the target antigen for IMA203?
IMA203 is directed against an HLA-A*02-presented antigen, PRAME.
What is the primary indication being investigated for IMA203?
The primary indication being investigated for IMA203 is melanoma, specifically metastatic melanoma in the Phase 3 trial.
Filing Stats: 2,156 words · 9 min read · ~7 pages · Grade level 13.2 · Accepted 2024-10-10 06:32:15
Filing Documents
- dp219157_6k.htm (6-K) — 36KB
- dp219157_ex9901.htm (EX-99.1) — 55KB
- dp219157_ex9902.htm (EX-99.2) — 57KB
- dp219157_ex9903.htm (EX-99.3) — 129KB
- image_001.jpg (GRAPHIC) — 1KB
- image_002.jpg (GRAPHIC) — 32KB
- image_003.jpg (GRAPHIC) — 31KB
- image_004.jpg (GRAPHIC) — 17KB
- image_005.jpg (GRAPHIC) — 25KB
- image_006.jpg (GRAPHIC) — 4KB
- image_007.jpg (GRAPHIC) — 77KB
- image_008.jpg (GRAPHIC) — 418KB
- image_009.jpg (GRAPHIC) — 258KB
- image_010.jpg (GRAPHIC) — 74KB
- image_011.jpg (GRAPHIC) — 148KB
- image_012.jpg (GRAPHIC) — 223KB
- image_013.jpg (GRAPHIC) — 98KB
- image_014.jpg (GRAPHIC) — 87KB
- image_016.jpg (GRAPHIC) — 109KB
- image_017.jpg (GRAPHIC) — 120KB
- image_018.jpg (GRAPHIC) — 65KB
- image_019.jpg (GRAPHIC) — 81KB
- image_020.jpg (GRAPHIC) — 168KB
- image_021.jpg (GRAPHIC) — 120KB
- image_022.jpg (GRAPHIC) — 71KB
- image_023.jpg (GRAPHIC) — 158KB
- image_024.jpg (GRAPHIC) — 117KB
- image_025.jpg (GRAPHIC) — 165KB
- image_026.jpg (GRAPHIC) — 208KB
- image_027.jpg (GRAPHIC) — 220KB
- image_029.jpg (GRAPHIC) — 181KB
- image_030.jpg (GRAPHIC) — 333KB
- image_032.jpg (GRAPHIC) — 63KB
- image_033.jpg (GRAPHIC) — 62KB
- image_034.jpg (GRAPHIC) — 418KB
- image_035.jpg (GRAPHIC) — 146KB
- image_036.jpg (GRAPHIC) — 199KB
- image_037.jpg (GRAPHIC) — 235KB
- image_038.jpg (GRAPHIC) — 64KB
- image_039.jpg (GRAPHIC) — 143KB
- image_040.jpg (GRAPHIC) — 266KB
- image_041.jpg (GRAPHIC) — 64KB
- image_042.jpg (GRAPHIC) — 148KB
- image_043.jpg (GRAPHIC) — 78KB
- image_044.jpg (GRAPHIC) — 289KB
- image_045.jpg (GRAPHIC) — 128KB
- image_046.jpg (GRAPHIC) — 89KB
- image_047.jpg (GRAPHIC) — 224KB
- image_048.jpg (GRAPHIC) — 169KB
- image_049.jpg (GRAPHIC) — 100KB
- image_050.jpg (GRAPHIC) — 148KB
- image_052.jpg (GRAPHIC) — 307KB
- image_053.jpg (GRAPHIC) — 74KB
- image_054.jpg (GRAPHIC) — 66KB
- image_055.jpg (GRAPHIC) — 146KB
- image_056.jpg (GRAPHIC) — 172KB
- image_057.jpg (GRAPHIC) — 125KB
- image_058.jpg (GRAPHIC) — 75KB
- image_059.jpg (GRAPHIC) — 87KB
- image_060.jpg (GRAPHIC) — 246KB
- image_061.jpg (GRAPHIC) — 70KB
- image_062.jpg (GRAPHIC) — 84KB
- image_063.jpg (GRAPHIC) — 95KB
- image_064.jpg (GRAPHIC) — 90KB
- image_065.jpg (GRAPHIC) — 76KB
- image_066.jpg (GRAPHIC) — 190KB
- image_067.jpg (GRAPHIC) — 74KB
- image_068.jpg (GRAPHIC) — 200KB
- image_069.jpg (GRAPHIC) — 206KB
- image_070.jpg (GRAPHIC) — 107KB
- image_071.jpg (GRAPHIC) — 145KB
- image_072.jpg (GRAPHIC) — 193KB
- image_073.jpg (GRAPHIC) — 117KB
- image_074.jpg (GRAPHIC) — 219KB
- image_075.jpg (GRAPHIC) — 71KB
- image_076.jpg (GRAPHIC) — 112KB
- image_077.jpg (GRAPHIC) — 214KB
- image_078.jpg (GRAPHIC) — 335KB
- image_079.jpg (GRAPHIC) — 231KB
- image_080.jpg (GRAPHIC) — 81KB
- image_081.jpg (GRAPHIC) — 226KB
- image_082.jpg (GRAPHIC) — 181KB
- image_083.jpg (GRAPHIC) — 215KB
- image_084.jpg (GRAPHIC) — 56KB
- image_085.jpg (GRAPHIC) — 305KB
- image_086.jpg (GRAPHIC) — 286KB
- image_087.jpg (GRAPHIC) — 248KB
- image_088.jpg (GRAPHIC) — 211KB
- image_089.jpg (GRAPHIC) — 82KB
- image_090.jpg (GRAPHIC) — 58KB
- image_091.jpg (GRAPHIC) — 134KB
- image_092.jpg (GRAPHIC) — 120KB
- image_093.jpg (GRAPHIC) — 62KB
- image_094.jpg (GRAPHIC) — 170KB
- image_095.jpg (GRAPHIC) — 175KB
- image_096.jpg (GRAPHIC) — 81KB
- image_097.jpg (GRAPHIC) — 90KB
- image_098.jpg (GRAPHIC) — 104KB
- image_099.jpg (GRAPHIC) — 190KB
- image_100.jpg (GRAPHIC) — 223KB
- image_101.jpg (GRAPHIC) — 53KB
- image_102.jpg (GRAPHIC) — 63KB
- image_103.jpg (GRAPHIC) — 218KB
- image_104.jpg (GRAPHIC) — 98KB
- image_105.jpg (GRAPHIC) — 270KB
- image_106.jpg (GRAPHIC) — 289KB
- image_107.jpg (GRAPHIC) — 79KB
- image_108.jpg (GRAPHIC) — 110KB
- image_109.jpg (GRAPHIC) — 204KB
- image_110.jpg (GRAPHIC) — 307KB
- image_111.jpg (GRAPHIC) — 162KB
- image_112.jpg (GRAPHIC) — 63KB
- image_114.jpg (GRAPHIC) — 332KB
- image_119.jpg (GRAPHIC) — 76KB
- image_120.jpg (GRAPHIC) — 84KB
- image_122.jpg (GRAPHIC) — 92KB
- image_123.jpg (GRAPHIC) — 102KB
- image_126.jpg (GRAPHIC) — 87KB
- 0000950103-24-014776.txt ( ) — 23367KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. IMMATICS N.V. Date: October 10, 2024 By: /s/ Harpreet Singh Name: Harpreet Singh Title: Chief Executive Officer